Langerhans-cell histiocytosis 'insight into DC biology'

被引：116

作者：

Laman, JD

Leenen, PJM

Annels, NE

Hogendoorn, PCW

Egeler, RM

机构：

[1] Erasmus MC, Dept Immunol, NL-3000 DR Rotterdam, Netherlands

[2] Leiden Univ, Ctr Med, Dept Pediat Immunol, NL-2300 RC Leiden, Netherlands

[3] Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RC Leiden, Netherlands

[4] Leiden Univ, Ctr Med, Dept Oncol, NL-2300 RC Leiden, Netherlands

[5] Leiden Univ, Ctr Med, Dept Bone Marrow Transplant, NL-2300 RC Leiden, Netherlands

[6] Leiden Univ, Ctr Med, Dept Autoimmune Dis, NL-2300 RC Leiden, Netherlands

[7] Leiden Univ, Ctr Med, Dept Pathol, NL-2300 RC Leiden, Netherlands

来源：

TRENDS IN IMMUNOLOGY | 2003年 / 24卷 / 04期

关键词：

D O I：

10.1016/S1471-4906(03)00063-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Langerhans-cell histiocytosis (LCH) is caused by an uncontrolled pathogenic clonal proliferation of dendritic cells (DCs) with Langerhans-cell (LC) characteristics. LCH cells are arrested in an immature, partially activated stage and show a deviant regulation of cell division. Their aberrant interactions with T cells and the lesional microenvironment are typified by high level production of diverse cytokines. Chemokine and chemokine receptor patterns probably explain LCH predilection sites and lesion composition, reminiscent of chronic granulomatous inflammation. Recent advances in LCH immunology suggest that clonal changes in DCs might underlie the aberrant immune interaction with T cells, leading to a unique pathological picture, which combines features of carcinogenesis and chronic inflammation.

引用

页码：190 / 196

页数：7

共 40 条

[1]

ABDELATIF OMA, 1990, ARCH PATHOL LAB MED, V114, P1254

[2]

Arceci Robert J, 2002, Hematology Am Soc Hematol Educ Program, P297

[3]

Clinical aspects of Langerhans cell histiocytosis [J].